Displaying 1 - 7 of 7
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Displaying 1 - 7 of 7